<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26693" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Paroxetine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shrestha</surname>
            <given-names>Prabina</given-names>
          </name>
          <aff>Ross Un School of Medicine/Kern MC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fariba</surname>
            <given-names>Kamron A.</given-names>
          </name>
          <aff>University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdijadid</surname>
            <given-names>Sara</given-names>
          </name>
          <aff>UCLA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prabina Shrestha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamron Fariba declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Abdijadid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26693.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It is used to treat several diseases, including major depressive disorder, obsessive-compulsive disorder, social anxiety disorder, panic disorder, posttraumatic stress disorder, generalized anxiety disorder, and premenstrual dysphoric disorder. It is used in the treatment of hot flashes and night sweats that are associated with menopause. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, monitoring, and toxicity of paroxetine, so providers can direct patient therapy in treating conditions for which it is indicated as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of paroxetine.</p></list-item><list-item><p>Outline the indications for initiating therapy with paroxetine.</p></list-item><list-item><p>Review the adverse event profile for paroxetine.</p></list-item><list-item><p>Review the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from therapy with paroxetine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26693&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26693">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26693.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Paroxetine is a selective serotonin reuptake inhibitor (SSRI) and, as such, is identified as an antidepressant. It is FDA approved for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), social anxiety disorder (SAD), panic disorder, posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), and premenstrual dysphoric disorder (PMDD), vasomotor symptoms associated with menopause.<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>&#x000a0;Paroxetine is not FDA approved for use in&#x000a0;children and adolescents less than 18 years of age; however, clinicians use it off-label in this group.&#x000a0;</p>
        <p>
<bold>Off-Label Use</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Obsessive-compulsive disorder (in children and adolescents)</p>
          </list-item>
          <list-item>
            <p>Social anxiety disorder (in children and adolescents)</p>
          </list-item>
          <list-item>
            <p>Separation anxiety&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dysthymia</p>
          </list-item>
          <list-item>
            <p>Body dysmorphic disorder</p>
          </list-item>
          <list-item>
            <p>Postpartum depression</p>
          </list-item>
          <list-item>
            <p>Premature ejaculation</p>
          </list-item>
          <list-item>
            <p>Malignancy related pruritus unresponsive to standard treatment</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26693.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>As an SSRI class drug, paroxetine's signature mechanism of action is to block the serotonin reuptake transporter (SERT) and thus increase the concentration of synaptic serotonin. Current theory suggests that the diminished serotonin concentration in the depressed brain induces the upregulation of serotonergic receptors. By increasing the synaptic serotonin concentration, paroxetine thus induces the downregulation of the previously upregulated serotonin receptors, thus normalizing the receptor concentration.<xref ref-type="bibr" rid="article-26693.r2">[2]</xref>&#x000a0;Furthermore,&#x000a0;in a radioligand study, paroxetine showed&#x000a0;some affinity for muscarinic, adrenergic (alpha and beta), dopaminergic (D2), serotonergic (5-HT2), and histaminergic (H1) receptors.<xref ref-type="bibr" rid="article-26693.r3">[3]</xref>&#x000a0;These receptors have also appeared to contribute to its antidepressant effects and its side effect profile.&#x000a0;</p>
      </sec>
      <sec id="article-26693.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Paroxetine is administered orally. The medication should be titrated based on the patient's symptoms and tolerance to dosage. The drug can be taken with or without food. In addition to regular tablets, it is available in a controlled-release tablet and liquid form. Paroxetine may be administered at any time of the day, depending on toleration.</p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>The steady-state mean value of T1/2 is 21 hours. Paroxetine undergoes metabolism via hepatic CYPP450 2D6. The urine excretes 2%, 62% metabolized over a 10-day post-dosing period, 36% excreted in the feces. Paroxetine inhibits CYP2D6 and, thus, its own metabolism; plasma concentrations can potentially double following dosage increases of 50%.<xref ref-type="bibr" rid="article-26693.r4">[4]</xref></p>
        <p>
<bold>For Major Depression&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>Immediate-release formulas</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: start with 20 mg by mouth daily and increase by 10 mg weekly with a max of 50 mg per day.</p>
          </list-item>
          <list-item>
            <p>Geriatric adults: start with 10 mg&#x000a0;by mouth daily and then increase by 10 mg weekly with a max dose of 40 mg per day&#x000a0;orally.</p>
          </list-item>
        </list>
        <p>Controlled-release formulas:</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: Start with 25 mg&#x000a0;by mouth daily, then increase by 12.5 mg weekly with a max of 62.5 mg.</p>
          </list-item>
          <list-item>
            <p>Geriatrics: Start with 12.5 mg&#x000a0;by mouth once daily, then increase to 12.5 if needed weekly.</p>
          </list-item>
        </list>
        <p>
<bold>Generalized Anxiety Disorder&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>Immediate release formulas</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: 20 mg&#x000a0;by mouth once daily. Titrate the dose by 10 mg per day at weekly intervals if required with a max dose of 60 mg per day.</p>
          </list-item>
          <list-item>
            <p>Geriatric Adults: 10 mg&#x000a0;by mouth once daily and titrate 10 mg per day at weekly intervals. Usually effective at 20 mg&#x000a0;by mouth daily but can increase up to 40 mg per day.</p>
          </list-item>
        </list>
        <p>
<bold>Premenstrual Dysphoric Disorders&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>Controlled-release tablet</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult Females: 12.5 mg per day orally. Effective doses were between 12.5 to 25 mg per day.</p>
          </list-item>
        </list>
        <p>Immediate-release formulation</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult females: 5 mg per day to 30 mg per day.</p>
          </list-item>
        </list>
        <p>
<bold>Vasomotor Disorder Secondary to Menopause&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>Controlled release tablets: 12.5 mg&#x000a0;by mouth daily and titrated to 25 mg&#x000a0;by mouth weekly.</p>
        <p>
<bold>Obsessive-Compulsive Disorder</bold>
<bold>&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>Immediate release formulation</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult: 20 mg once daily and increase by 10 mg per day weekly intervals if tolerated. Titrate the dose include 40 mg&#x000a0;orally once daily with a max of 60 mg per day.</p>
          </list-item>
          <list-item>
            <p>Geriatric: 10 mg once daily. If needed, increase to 10 mg per day at weekly intervals with a max dose of 40 mg per day.</p>
          </list-item>
          <list-item>
            <p>Children and adolescents seven years and older: 10 to 50 mg by mouth; 10 mg per day increase at intervals of a week with a max of 50 mg per day.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Panic Disorder&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>Immediate-release formulation</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult: 10 mg&#x000a0;orally once daily and increase the dose to 10 mg per day at weekly intervals with a target dose of 40 mg per day with a max dose of 60 mg per day.</p>
          </list-item>
          <list-item>
            <p>Geriatrics: 10 mg&#x000a0;orally once daily and increase 10 mg per day at weekly intervals with a target dose of 40 mg per day. Max dose is 40 mg per day.</p>
          </list-item>
          <list-item>
            <p>Children and adolescents seven years and older: 10 mg orally; max dose 40 mg per day.</p>
          </list-item>
        </list>
        <p>Controlled-release tablets</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: 12.5 mg&#x000a0;orally once daily and increase by 12.5 mg at weekly intervals. The effective dose range is 12.5 to 75 mg per day with a max dose of 75 mg&#x000a0;daily.</p>
          </list-item>
          <list-item>
            <p>Geriatrics Adults: 12 mg&#x000a0;by mouth daily and increase by 12.5 mg at weekly intervals. The effective dose is 12.5 to 75 mg per day. The recommended maximum dose is 50 mg per day.</p>
          </list-item>
        </list>
        <p>
<bold>Post Traumatic Stress Disorder&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>Immediate-release formulation</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: 20 mg&#x000a0;by mouth daily. Effective doses range from 20 to 50 mg per day. With a max dose of 60 mg per day.</p>
          </list-item>
          <list-item>
            <p>Geriatrics: 10 mg&#x000a0;by mouth once daily and increase by 10 mg&#x000a0;per&#x000a0;day at a weekly interval. Max dose of 40 mg&#x000a0;per&#x000a0;day&#x000a0;orally.</p>
          </list-item>
        </list>
        <p>
<bold>Social Phobias&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>Immediate release formulation</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult: 20 mg&#x000a0;per&#x000a0;day orally; Effective dose range is 20 to 60 mg&#x000a0;per&#x000a0;day; Titrate to 10 mg&#x000a0;per&#x000a0;day weekly; Max dose of 60 mg&#x000a0;per&#x000a0;day.</p>
          </list-item>
          <list-item>
            <p>Geriatric adults: 10 mg&#x000a0;orally&#x000a0;and titrate by 10 mg&#x000a0;per&#x000a0;day; target the dose 20 mg per day with a max dose of 40 mg&#x000a0;per&#x000a0;day.</p>
          </list-item>
          <list-item>
            <p>Children and adolescents eight years and older: 10 mg&#x000a0;per&#x000a0;day and titrate 10 mg&#x000a0;per&#x000a0;day at a weekly interval; The maximum dose of 50 mg&#x000a0;per&#x000a0;day&#x000a0;orally.</p>
          </list-item>
        </list>
        <p>Controlled release formulation</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult: 12.5 mg&#x000a0;per&#x000a0;day&#x000a0;orally and titrate at intervals of at least one week and an increase of 12.5 mg&#x000a0;per&#x000a0;day; Max dose of 37.5 mg&#x000a0;per&#x000a0;day&#x000a0;orally.</p>
          </list-item>
        </list>
        <p>
<bold>Renal Impairment: Adults&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>For patients with renal impairment, the dosage is based on&#x000a0;creatinine clearance, as shown below.</p>
        <list list-type="bullet">
          <list-item>
            <p>If the CrCL is 30 to 60 ml per minute: No need to change the dosing.</p>
          </list-item>
          <list-item>
            <p>If CrCl is less than 30 ml&#x000a0;per&#x000a0;minute:
<list list-type="bullet"><list-item><p>Immediate release formulation: 10 mg&#x000a0;per&#x000a0;day; increase if needed by 10 mg&#x000a0;per&#x000a0;day increments at an interval of at least a week; maximum dose: 40 mg&#x000a0;per&#x000a0;day.</p></list-item><list-item><p>Controlled release formulation: 12.5 mg&#x000a0;per&#x000a0;day; increase if needed by 12.5 mg&#x000a0;per&#x000a0;day increments at interval one week; maximum dose: 50 mg&#x000a0;per&#x000a0;day.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Hepatic Impairment Adults&#x000a0;</bold>
<xref ref-type="bibr" rid="article-26693.r1">[1]</xref>
</p>
        <p>In hepatic impairment, plasma concertation of two times normal can occur.</p>
        <list list-type="bullet">
          <list-item>
            <p>If mild to moderate: no change in dosage.</p>
          </list-item>
          <list-item>
            <p>If severe
<list list-type="bullet"><list-item><p>Immediate-release formulations: 10 mg&#x000a0;per&#x000a0;day and, if needed, increase by 10 mg&#x000a0;per&#x000a0;day at intervals of 1 week; maximum dose of 40 mg&#x000a0;per&#x000a0;day.</p></list-item><list-item><p>Controlled release formulation: 12.5 mg&#x000a0;per&#x000a0;day; increase if needed by 12.5 mg&#x000a0;per&#x000a0;day increments at intervals of 1 week; maximum dose&#x000a0;is 50 mg&#x000a0;per&#x000a0;day.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26693.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Many of the side effects of paroxetine are dose-dependent. The most common side effects include drowsiness, dry mouth, loss of appetite, sweating, sleep disturbance, and sexual side effects. Clinicians can address sexual side effects medications like sildenafil). Discontinuation syndrome is more common and more severe with paroxetine than with other SSRIs; this may be due in part to the fact that it inhibits its own metabolism. Withdrawal symptoms from discontinuation include dizziness, lethargy, nausea, vomiting, headache, fever, chills, vivid dreams, electric shock-like-sensation, dyskinesia, anxiety, crying, irritability, and depersonalization.<xref ref-type="bibr" rid="article-26693.r5">[5]</xref></p>
        <p>
<bold>Other Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Psychiatric:&#x000a0;Apathy and emotional flattening (indirect decrease of dopamine), hypomania, or mania (1%). In children and adolescents, and young adults (18&#x000a0;to 24 years of age), paroxetine&#x000a0;can increase the risk of suicide.
<list list-type="bullet"><list-item><p>Induction of agitation or manic state may represent an underlying bipolar condition that requires the addition of a mood stabilizer, lithium, an atypical antipsychotic, and/or the discontinuation of paroxetine.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Nervous system: Extrapyramidal symptoms, dizziness, headache, tremor</p>
          </list-item>
          <list-item>
            <p>Metabolic: hyponatremia (SIADH), weight gain</p>
          </list-item>
          <list-item>
            <p>Cardiovascular: Edema, chest pain, palpitations, tachycardia, vasodilation</p>
          </list-item>
          <list-item>
            <p>Dermatologic:&#x000a0;Alopecia, eczema, photosensitivity, purities</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal:&#x000a0;Constipation, diarrhea, nausea</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26693.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are only a few absolute contraindications for the use of paroxetine. Absolute contraindications include concurrent use of monoamine oxidase inhibitors (MAOIs), thioridazine, and pimozide. Concomitant use of MAOIs and paroxetine can precipitate serotonin syndrome. Concurrent use of thioridazine and paroxetine can induce cardiac arrhythmias; similar effects can occur with pimozide and paroxetine.<xref ref-type="bibr" rid="article-26693.r6">[6]</xref>&#x000a0;</p>
        <p>Precautions that should be acknowledged when prescribing paroxetine include concurrent tricyclic antidepressant (TCA) use, concomitant tamoxifen use, and drugs affecting hepatic metabolism.&#x000a0;Paroxetine inhibits TCA metabolism, leading to possible TCA toxicity. Tamoxifen is active once metabolized by CYP4502D6; thus, paroxetine essentially inactivates tamoxifen.&#x000a0;</p>
        <p>Paroxetine is not recommended for use during pregnancy or if breastfeeding. Based on epidemiological studies, infants exposed to paroxetine during the first trimester had an increased risk for cardiovascular malformations.<xref ref-type="bibr" rid="article-26693.r6">[6]</xref></p>
      </sec>
      <sec id="article-26693.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients initiated on paroxetine should initially receive close observation and be monitored for worsening clinical symptoms, behavior changes (mania, social function, anxiety), or suicidal ideations. Labs should include serum sodium concentration to rule out SIADH.<xref ref-type="bibr" rid="article-26693.r7">[7]</xref>&#x000a0;Vital signs should be monitored for signs of serotonergic hyperactivity.&#x000a0;Serotonin syndrome precipitates via the manifestation of changes in mental status, autonomic instability, gastrointestinal symptoms, hyperreflexia, and myoclonus. Serotonin syndrome is treated by discontinuing any of the offending agents. If symptoms continue to escalate, the clinician can administer cyproheptadine.<xref ref-type="bibr" rid="article-26693.r8">[8]</xref></p>
      </sec>
      <sec id="article-26693.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Though it is rarely lethal in overdose by itself, patients can develop somnolence, nausea, tremor, heart rhythm disturbances, confusion, vomiting, dizziness, and mydriasis. During toxicity, a patient&#x02019;s airway, oxygenation, and ventilation require evaluation first. The treatment for overdose includes symptomatic supportive treatment. There is no specific treatment for paroxetine toxicity.<xref ref-type="bibr" rid="article-26693.r9">[9]</xref></p>
      </sec>
      <sec id="article-26693.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional teamwork&#x000a0;can impact a patient's&#x000a0;outcome positively. This team starts with the prescribing clinicians (MD, DO, PA, NP), who will make the initial determination for using paroxetine.&#x000a0;Open communication between various disciplines, such as pharmacy and psychiatry, can benefit the patient.<xref ref-type="bibr" rid="article-26693.r10">[10]</xref> Each department acknowledges what the patients' needs and implement the plan. The pharmacist can provide the dosing for the patient and monitor toxicity levels and consult with the prescriber for changes. Each patient is unique; some may require a different dosage because of renal or hepatic dysfunction. This approach allows the patient to have a correct dosage based on their co-morbid conditions. Nursing should be alert to signs of adverse drug events, improvement in status, or the need for further evaluation and report such to the clinician. The psychiatrist can also monitor the patient clinically for improvement, or if needed, make changes in the medication.&#x000a0;This interprofessional paradigm can improve patient outcomes through enhanced treatment strategies and information sharing. [Level 5]</p>
      </sec>
      <sec id="article-26693.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26693&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26693">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26693/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26693">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26693.s11">
        <title>References</title>
        <ref id="article-26693.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Germann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tikhomirova</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Paroxetine hydrochloride.</article-title>
            <source>Profiles Drug Subst Excip Relat Methodol</source>
            <year>2013</year>
            <volume>38</volume>
            <fpage>367</fpage>
            <page-range>367-406</page-range>
            <pub-id pub-id-type="pmid">23668408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26693.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amidfar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YK</given-names>
              </name>
            </person-group>
            <article-title>Recent Developments on Future Antidepressant-related Serotonin Receptors.</article-title>
            <source>Curr Pharm Des</source>
            <year>2018</year>
            <volume>24</volume>
            <issue>22</issue>
            <fpage>2541</fpage>
            <page-range>2541-2548</page-range>
            <pub-id pub-id-type="pmid">30073919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26693.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Harten</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of selective serotonin reuptake inhibitors.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1993</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-20</page-range>
            <pub-id pub-id-type="pmid">8384945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26693.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uttamsingh</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gallegos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Harbeson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bridson</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Zelle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>354</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-54</page-range>
            <pub-id pub-id-type="pmid">25943764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26693.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bos</surname>
                <given-names>JHJ</given-names>
              </name>
              <name>
                <surname>Wilffert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hak</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.</article-title>
            <source>Pharmacoepidemiol Drug Saf</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>621</fpage>
            <page-range>621-629</page-range>
            <pub-id pub-id-type="pmid">29575226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26693.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hieronymus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lisinski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression.</article-title>
            <source>Mol Psychiatry</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>1731</fpage>
            <page-range>1731-1736</page-range>
            <pub-id pub-id-type="pmid">29155804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26693.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Magalh&#x000e3;es</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alves</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Llerena</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falc&#x000e3;o</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Drug Monitoring of Fluoxetine, Norfluoxetine and Paroxetine: A New Tool Based on Microextraction by Packed Sorbent Coupled to Liquid Chromatography.</article-title>
            <source>J Anal Toxicol</source>
            <year>2017</year>
            <month>Sep</month>
            <day>01</day>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>631</fpage>
            <page-range>631-638</page-range>
            <pub-id pub-id-type="pmid">28873974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26693.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Bronstein</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin reuptake inhibitor exposure.</article-title>
            <source>Top Companion Anim Med</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-7</page-range>
            <pub-id pub-id-type="pmid">23796482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26693.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calisto</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Otero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esteves</surname>
                <given-names>VI</given-names>
              </name>
            </person-group>
            <article-title>Adsorptive removal of pharmaceuticals from water by commercial and waste-based carbons.</article-title>
            <source>J Environ Manage</source>
            <year>2015</year>
            <month>Apr</month>
            <day>01</day>
            <volume>152</volume>
            <fpage>83</fpage>
            <page-range>83-90</page-range>
            <pub-id pub-id-type="pmid">25617872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26693.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pontefract</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Vallance</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marriott</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Redwood</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The impact of computerised physician order entry and clinical decision support on pharmacist-physician communication in the hospital setting: A qualitative study.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>e0207450</fpage>
            <pub-id pub-id-type="pmid">30444894</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
